

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES**

NAME: Weiss, Stanley H., M.D.

eRA COMMONS USER NAME: SHWEISS

POSITION TITLE: Professor of Medicine, Rutgers Biological and Health Sciences-NJ Medical School (NJMS)
Professor of Epidemiology, Rutgers School of Public Health (SPH)
Associate, Rutgers Cancer Institute of New Jersey

EDUCATION/TRAINING: *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)*

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
Yale College, New Haven, CT	BA	1975	Molecular Biophysics & Biochemistry
Harvard Medical School, Boston, MA	MD	1978	Medicine
Montefiore Hospital, Albert Einstein School of Medicine, Bronx NY		1983	Internal Medicine Residency, PGY 1-3
Centers for Disease Control, Atlanta, GA			Epidemiology Research
National Cancer Institute, Bethesda, MD (Cancer Treatment)			Medical Oncology, Medical Staff Fellow
National Cancer Institute, Bethesda, MD (Epidemiology)		1987	Epidemiology, Medical Staff Fellow

A. Personal Statement

I have been responsible for the design of many interdisciplinary epidemiologic studies, beginning in the 1980's with multiple cohort studies of drug users. I have also been extensively involved in public health matters. My training in epidemiology has led to research in multiple fields, including drug use (including tobacco and alcohol), cancer, infectious diseases, asthma, public health, public policy, community-based interventional research, and quality assessment/quality improvement projects. Among my duties as a National Cancer Institute (NCI) Fellow were serving as the PI on multiple studies; designation by NCI to advise multiple other institutes and agencies such as: NIAID on designing its biospecimen repositories for their prospective MACS studies; the American Red Cross and NHLBI concerning HIV testing, HIV prevalence, and AIDS risk; NICHD on issues related to barrier protection; and as the lead from NIH on collaborative endeavors with NIDA. When I moved to the New Jersey Medical School (NJMS) in 1987, I continued and extended my collaborations with the NJ Dept. of Health (NJDOH), in particular related to the initial cohort of drug users I assembled within NJ. The studies I have led are multidisciplinary, melding questionnaire, clinical outcome data and state-of-the-art laboratory tests performed by collaborators from around the world. I also had a leadership role at The University Hospital in Newark as its Cancer Liaison Physician (4 terms) and vice-chair of its oncology committee. I am an Associate of the CINJ. Collaborations with the NJ State Cancer Registry and HIV/AIDS registry have led to approval by their respective IRBs and Rutgers, enabling us to resume matching our cohort subjects to those registries, and incorporating modern advances in registry matching techniques. I had extensive discussions with Dr. Jonathan Pollock, chief of the Genetics and Molecular Neurobiology Research Branch at NIDA, which in 2017 culminated in my appointment as a member of the NIDA Genetics Consortium (NGC). This in turn led to collaborations with Dr. Eric Johnson at RTI International, other members of the NGC, and NIDA's contractor, RUCDR Infinite Biologics, which processed. Over the last 20 years, I led a county cancer coalition that was succeeded by a bi-county regional chronic disease coalition, with unbroken support from the NJDOH for 20 years. We developed a web site for this coalition, recently updated as <https://epwcnj.org/> I have been working closely with our local health officers, who alerted me several years ago to evolving issues related to hookah, vaping and ENDS, leading us to construct a web page on the EPWC site devoted to these issues and convening multiple open meetings. Recently, I have assisted INEP on a

development of a policy statement related to vaping and ENDS (now undergoing review by the 25 constituent epidemiologic societies). I am a member of the State Epidemiologic Outcomes Workgroup for the State of New Jersey as well as the local PAC/PACDATA for Essex County, which deal with tobacco, alcohol, and other drugs issues.

Ongoing and recently completed projects that I would like to highlight include:

National Institutes of Health, National Institute on Drug Abuse. The Epidemiology of the Weiss Cohort Project (also known as “Outcome Assessments of Demographically Diverse Long-term Cohorts of Persons at High HIV Risk Enrolled from Drug Abuse Treatment Programs in the 1980s across the U.S.”

Stanley H. Weiss, MD – PI. Begun 8/15/2020.

1R01DA050495-01

New Jersey Department of Health, Division of HIV, STD, and TB Services, DHSTS COVID-19 Vaccination Supplement 2022 (prime sponsor is the CDC). Engaging Women of Color about COVID-19 Vaccinations.

Stanley H. Weiss, MD, PI. 4/1/2022 – 6/30/23.

Bloomberg Philanthropies, through the City of Paterson, Bloomberg Mayors Challenge awardee. (We are one of 15 cities internationally, and one of the three cities in the US, total award \$1,000,000 direct costs.) RealFix (also known as “Appropriate Medication Assisted Treatment Anytime, Anywhere In 90 Minutes” [AMATAA]).

Stanley H. Weiss, MD, PI of Rutgers NJMS portion of project. Awarded on the period 07/01/2022 – 01/31/2025.

National Council on Aging. Covid-19 and influenza in the elderly. Awarded 3/22/2023. Stanley H. Weiss, PI.

New Jersey Department of Health, Division of Community Health Services, Community Health and Wellness Unit, Office of Cancer Control and Prevention (partially sponsored by the CDC). Essex-Passaic Wellness Coalition (Region 2 chronic disease coalition). Daniel M. Rosenblum, PhD, PI. Stanley H. Weiss, founder and director.

Continuous funding since NJ FY 2013 (and continuous funding to Dr. Weiss of one of this coalition’s predecessors, the Essex County Cancer Coalition, from FY 2005 through FY 2012)

NJ Department of Health, Office of Population Health, NJ Health Equity Response to COVID-19 Activity C2

2022: COVID-19 Community Coalitions for Individuals with Chronic Disease (prime sponsor is the CDC)

Essex-Passaic COVID-19 Activity C2 2022. Daniel M. Rosenblum, PhD, PI. Stanley H. Weiss, MD. Consultant.

Awarded: 08/01/2021 – 05/31/2023.

Citations:

1. **Weiss SH**, Wormser, GP. COVID-19: Understanding the science of antibody testing and lessons from the HIV epidemic. *Diagnostic Microbiology & Infectious Disease*. Sep 2020; 98(1):115078. <https://doi.org/10.1016/j.diagmicrobio.2020.115078>.
2. M Oremus, R Taylor-Wilson, M Aldrich, K Bell, J Gaudino, S Palevsky, J Payne, C Raynes-Greenow, F Sim, M Smith, **S Weiss**, Y Zhang. The Role of Epidemiologists in SARS-CoV-2 and COVID-19 Research. *Public Health*. Jan 2021; 190:e3-e4. <https://doi.org/10.1016/j.puhe.2020.10.006>.
3. Choi CJ, **Weiss SH**, Umair N, Pyropoulos N. Cannabis use history is associated with increased prevalence of ascites among patients with nonalcoholic fatty liver disease: A nationwide analysis. *World Journal of Hepatology*. Nov 2020; 12(11): 993-1003. PMID: 33312424
URL: <https://www.wjgnet.com/1948-5182/full/v12/i11/993.htm>
DOI: <https://dx.doi.org/10.4254/wjh.v12.i11.993>
4. Choi C, Abougergi M, Peluso H, **Weiss SH**, Nasir U, Pyrsopoulos N. Cannabis use is associated with reduced 30-day all-cause readmission among hospitalized patients with irritable bowel syndrome: A nationwide analysis. *J Clin Gastroenterology*. 2022; 56(3):257-265. PMID: 33471483 DOI: [10.1097/MCG.0000000000001498](https://doi.org/10.1097/MCG.0000000000001498)

B. Positions and Honors

Positions and Employment

1987-1993 Assistant Professor, Department of Preventive Medicine and Community Health, University of Medicine and Dentistry of NJ (UMDNJ)/New Jersey Medical School (**NJMS**), Newark, NJ

1987-1993 Chief, AIDS & Retroviral Epidemiology, Dept. Prev. Medicine & Comm. Health, NJMS, Newark
 1988-2015 Assistant Professor, Division of Oncology, Dept. of Medicine, NJMS, Newark, NJ.
 1989-1997 Director, Division of Infectious Diseases Epidemiology, Dept. Preventive Medicine & CH
 1993-2004 Associate Professor, Dept. of Preventive Medicine & Community Health, NJMS, Newark, NJ
 2000-2013 Associate Professor, Quantitative Methods Division, UMDNJ School of Public Health.
 2004-2013 Professor, Department of Preventive Medicine and Community Health, NJMS, Newark, NJ
 2005-2013 Professor, Department of Quantitative Methods, UMDNJ School of Public Health.
 2008-2019 Cancer Liaison Physician to the Commission on Cancer of the American College of Surgeons for the University Hospital/NJMS Oncology Program
 2012-2019 Appointed by Univ Hospital Oncology Committee as Vice-chair of the Oncology Committee.
 2013-2015 Professor, Dept. of Preventive Medicine and Community Health, Rutgers–NJMS, Newark.
 2013-2015 Professor, Department of Quantitative Methods, Rutgers School of Public Health.
 2015-present Professor, Dept. Medicine, Rutgers, Rutgers Biomedical and Health Sciences (**RBHS**), NJMS
 2015-present Professor, Department of Biostatistics and Epidemiology, Rutgers School of Public Health.
 2017-2021 Scientific Research Mentor, Department of Medicine, Rutgers–NJMS, Newark.
 2017-2021 Senior Research Advisor, Dept. of Medicine, NJMS.
 2018-present Associate Member, Rutgers Cancer Institute of NJ (CINJ), Cancer Prevention and Control.

Licensure and Certifications

1979 New York Medical License (currently inactive)
 1979 Diplomate, National Board of Medical Examiners
 1981 Specialty Board: Internal Medicine, Certified
 1985 Sub-Specialty Board: Medical Oncology, Certified
 1987 New Jersey Medical License
 1989 Fellow, Infectious Diseases Society of America (currently inactive)
 1992 Fellow, American College of Physicians (FACP)
 1997 American College of Epidemiology (elected Member 1997 and as Fellow 2006)

Other Experience and Professional Memberships

1981-1982 Assistant Attending, Dept. of Medicine, Montefiore Hospital and Medical Center, Bronx, NY
 1982-1987 Active Medical Staff, National Institutes of Health Clinical Center
 1986-1988 Adjunct Assistant Professor, Dept. Preventive Medicine/Biometrics, USUHS, Bethesda, MD
 1987 Special Consultant, World Health Organization, Contraceptive Methods and HIV Infection
 1988-current Member, University Hospital Bioethics Committee
 1988 NIH NCI Ad Hoc Study Section, Epidemiologic Studies HIV-Associated Malignancies, Bethesda
 1989 Keynote Speaker, University World Health Day
 1990-1993 Member, Editorial Board, AIDS
 1990-1998 Member, Editorial Board, AIDS Research and Human Retroviruses
 1998-2000, 2015-17, 2018-present Member (elected), New Jersey Medical School Faculty Council
 1993-1994 Meeting Chairman, 6th International Conference on Human Retrovirology: HTLV
 1994 -current Executive Board, NJ Public Health Association
 1994 Member, Epidemiology II Review Com, US Army Medical Research & Development Command
 1994 Inaugural Speaker, 2nd National Spanish Conference on HIV, Caceres, Spain
 1994-1996 Co-chair, Epidemiology Section Program Committee, American Public Health Association
 1994-1998 Advisory Board, International Retrovirology Association – HTLV & Related Viruses
 1995-1997 Chair, AIDS Committee, NJ Public Health Association
 1996- Senior Research Fellow, Windwards Island Research and Education Foundation
 1996 Guest Expert Consultant, FDA Blood Products Advisory Committee
 1997 Advisor, Cross-species infectivity issues for the NIH, CDC, FDA and HRSA
 1997 NIH, FDA, CDC & HRSA Panel Moderator. Cross-species Infectivity & Pathogenesis Meeting.
 1997-2003 Epidemiologist, Asthma and Allergy Research Center, New Jersey Medical School
 1997-2003+ multiple other years Member, Governing Council of American Public Health Association
 1998-2002 Member, Institutional Review Board, NJMS
 2000-current Founding Chair, Epidemiology Section, NJ Public Health Association
 2000-2002 Member, Nominating Committee, American Public Health Association (APHA)
 2001 Member, Program & Awards Committees, North American Congress of Epidemiology, Toronto
 2003-2009 APHA Epidemiology Section, 2 years each: Chair-elect, Chair, Immediate Past Chair
 2003-2006 Member, APHA Science Board (2 years as Vice-chair)
 2004-2007 Member. APHA Joint Policy Committee

2004-current	Trustee, Yale Club of Central New Jersey (YCCNJ) (five consecutive three-year terms)
2005	Member, Intersectional Council Steering Committee, APHA
2006	Organizing Committee, Program Comm & Chair of Awards Comm, 2 nd (North) American Congress of Epidemiology, Seattle, WA. Plenary lecture on behalf of the APHA
2005-current	Faculty Officer of Alpha Omega Alpha (Medical Honor Society), Beta Chapter of NJ; Chair of medical student selection committee; Chair of medical student research award committee
2006	Founding Member, Joint Policy Committee of the Societies of Epidemiology Societies, and from 2006-2009 the primary representative of the APHA Epidemiology Section to it.
2006-2008	Member, Governing Council of American Public Health Association
2008-2019	Cancer Liaison Physician for Rutgers CINJ at University Hospital (Newark) to the Commission on Cancer of the American College Surgeons. (Served 4 consecutive 3-year terms.)
2007-2014	Vice-chair (elected, 2 yrs.); Chair (elected, 2 terms, 4 yrs.); post-Chair (1+ yrs.) of the Joint Policy Committee of the Societies of Epidemiology – see www.ijpc-se.org . In December 2013, the societies officially approved an organizational name to the International Joint Policy Committee of the Societies of Epidemiology (IJPC-SE). In April 2018, name changed again, to the International Network for Epidemiology in Policy (INEP); Dr. Weiss remains an advisor.
2010-2014	Chair, International Joint Policy Committee of the Societies of Epidemiology. (Chair-elect 2008-2009; Immediate Past Chair, 2014-2016)
2012-2019	Oncology Committee Vice-chair, Rutgers Cancer Institute of New Jersey at University Hospital (formerly University Hospital) in Newark NJ. (Served 3 consecutive 3-year terms.)
2015-current	Member, RBHS Conflict of Interest Committee.
2014-2016	Organizing Committee, Epidemiology Congress of the Americas, Miami FL, June 2016.
2018-current	Member, State Epidemiologic Outcomes Workgroup, State of New Jersey.
2018-current	Member, PAC/PACDATA, Essex County.
2023	President-elect, NJMS Faculty Organization.

HONORS

1971	Barge Prize for Excellence in Mathematics, Yale College, New Haven, CT
1971-1974	New York State Governor's Committee Award for Academic Achievement
1975-1978	Joseph Collins Scholar, Harvard Medical School, Boston, MA
1985	American Society of Clinical Oncology Travel Award
1991	Finalist, Merck/SER Fellowship Competition
2003	Faculty Inductee (NJMS), Alpha Omega Alpha (Medical Honor Society), Beta Chapter of NJ
2007	Faculty Community Service Award, UMDNJ-School of Public Health, Newark, NJ
2007	"In the Know" National Award, The Prostate Net
2007	Dr. Ezra Mundy Hunt Award for outstanding service and leadership, NJ Public Health Assoc
2009	Cancer Liaison Physician Outstanding Performance Award, Commission on Cancer of the American College of Surgeons
2010	CAREforAIRnj Award for Community Outreach/Action/Advocacy, American Lung Assoc of NJ
2012	Dennis J. Sullivan Award, New Jersey Public Health Association
2015	Kick-off Lecture, NJMS Summer Research Program, Office of the Research Dean.
2015	Wade Hampton Frost Lectureship Award from the American Public Health Epidemiology Section of the APHA (its highest award) for excellence in research and public health.
2019	Elected Fellow of the Royal College of Physicians of Edinburgh.
2021	John Snow Award, from the American Public Health Epidemiology Section of the APHA, a lifetime achievement award in epidemiology for major contributions to public health.
2022	NJMS Faculty Organization Distinguished Career Award, Clinical Award, which celebrates dedication of both one's life and work career to medical excellence.

C. Contributions to Science

1. Contributions to understanding the evolving AIDS epidemic – epidemiology & lab testing

- a. **Weiss SH**, Lombardo J, Michaels J, Sharer LR, Tayyarah M, Leonard J, Mangia A, Kloser P, Sathe S, Kapila R, Williams NM, Altman R, French J, Parkin WE. AIDS due to HIV-2 infection - New Jersey. Morbidity and Mortality Weekly Report 37:33-35, 1988. Also published in: The Journal of the American Medical Association 259:969-972, 1988.
- b. Lombardo JM, Horsburgh CR, Denny TN, Michaels J, Schable C, Meyerhofer MI, Schriver K, Sharer LR, Ou C-Y, Rayfield MA, Kloser PC, Oleske JM, Schochetman G, **Weiss SH**. Evaluation of an atypical

HIV-1 antibody serologic pattern leading to detection of HIV type 2 infection in North America. Archives of Pathology and Laboratory Medicine 113:1245-1249, 1989.

- c. **Weiss SH**. Factors influencing long-term nonprogression of HIV disease: Editorial comment. The AIDS Reader 4(6):200-201, 1994.
- d. **Weiss SH**, Cowan EP. Laboratory detection of human retroviruses. In: *AIDS and Other Manifestations of HIV Infection*, fourth edition, ed. Gary P. Wormser, Elsevier Science, London. Chapter 8, pp. 147-183, 2004.

2. Contributions to the epidemiology of HIV/AIDS in drug users

- a. Lee HH, **Weiss SH**, Brown LS, Mildvan D, Shorty V, Saravolatz L, Chu A, Ginzburg HM, Markowitz N, DesJarlais DC, Blattner WA, Allain J-P. Patterns of HIV-1 and HTLV-I/II in intravenous drug abusers from the Middle Atlantic and Central regions of the USA. Journal of Infectious Disease, 162:347-352, 1990.
- b. Beretta A, **Weiss SH**, Rappocciolo G, Mayur R, Cosma A, De Santis C, Quirinale J, Robboni P, Shearer GM, Berzofsky JA, Villa ML, Siccardi AG, Clerici M. Seronegative intravenous drug users at risk for HIV exposure exhibit antibodies to HLA class I antigens and T-cells specific for HIV envelope. The Journal of Infectious Diseases 173(2):472-476, 1996. DOI:10.1093/infdis/173.2.472
- c. Zangerle R, Fuchs D, Rossler H, Reibnegger G, Riemer Y, **Weiss S**, Fritsch P, Wachter H. Trends in HIV infection among intravenous drug users in Innsbruck. J Acq Immune Deficiency Syndromes 5:865-871, 1992.
- d. **Weiss SH**, Klein CW, Quirinale J. Safe sex? Misconceptions, gender differences and barriers among injection drug users: a focus group approach. AIDS Education and Prevention 5(4):279-293, 1993.

3. Evolving epidemiology of HTLV-II: From 1st HTLV-II case in a drug user to defining its extent

- a. Hahn BH, Popovic M, Kalyanaraman VS, Shaw GM, LoMonico A, **Weiss SH**, Wong-Staal F, Gallo RC. Detection and characterization of an HTLV-II provirus in a patient with AIDS. Acquired Immune Deficiency Syndrome, Alan R. Liss, Inc., New York, NY, pp. 73-81, 1984.
- b. Robert-Guroff M, **Weiss SH**, Giron J, Jennings AM, Ginzburg HM, Margolis I, Blattner WA, Gallo RC. Prevalence of antibodies to HTLV-I, -II, and -III in intravenous drug abusers from an AIDS endemic region. The J of American Medical Assoc 255:3133-3137, 1986. doi:10.1001/jama.1986.03370220095034. PMID: 3009910
- c. Palumbo PE, **Weiss SH**, McCreedy B, Alexander SS, Denny TN, Klein CW, Altman R. Evaluation of HTLV infection in a cohort of injecting drug users. Journal of Infectious Disease 166:896- 899, 1992.
- d. **Weiss SH**. Editorial: The evolving epidemiology of human T lymphotropic virus type II. Journal of Infectious Diseases 169:1080-1083, 1994.

4. Selected other studies related to HIV/AIDS

- a. **Weiss SH**, Saxinger WC, Rechtman D, Grieco MH, Nadler J, Holman S, Ginzburg HM, Groopman JE, Goedert JJ, Markham PD, Gallo RC, Blattner WA, Landesman SH. HTLV-III infection among health care workers: association with needle-stick injuries. Journal of the American Medical Assoc 254:2089-2093, 1985. doi:10.1001/jama.1985.03360150065025. 30.39 Impact Factor.
- b. **Weiss SH**, Goedert JJ, Gartner S, Popovic M, Waters D, Markham P, diMarzo-Veronese F, Gail MH, Barkley WE, Gibbon J, Gill FA, Leuther M, Shaw GM, Gallo RC, Blattner WA. Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers. Science 239:68-71, 1988. doi:10.1126/science.3336776.
- c. Reitz MS, Hall L, Robert-Guroff M, Lautenberger J, Hahn BM, Shaw GM, Kong LI, **Weiss SH**, Waters D, Gallo RC, Blattner WA. Viral variability and serum antibody response in a laboratory worker infected with HIV type 1 (HTLV type IIIB) AIDS Research and Human Retroviruses 10(9):1143-1155, 1994.
- d. **Weiss SH**, Klein CW, Mayur RK...Denny TN. Idiopathic CD4+ T-lymphocytopenia. Lancet 340:608-609, 1992.